Form 4: ZyVersa Therapeutics CEO Stephen Glover Granted Stock Options, Corrects Reporting Error
SEC Form 4 Filing
ZyVersa Therapeutics CEO Stephen C. Glover was granted stock options and a previous reporting oversight was corrected via a Form 4 filing with the SEC.
Summary
- Stephen C. Glover, CEO of ZyVersa Therapeutics, was granted stock options on May 24, 2023.
- The grant involved 1,627 stock options with an exercise price of $152.46.
- The options vest annually in three equal installments starting May 24, 2024.
- The filing also corrects an administrative oversight regarding the reporting of these options.
- A Power of Attorney was executed on December 13, 2022, granting Peter Wolfe and Karen A. Cashmere the authority to act on Glover's behalf for SEC filings.
- The share and dollar amounts reflect a 1-for-35 reverse stock split on December 4, 2023, and a 1-for-10 reverse stock split on April 25, 2024.
Sentiment
Score: 6
Explanation: The document is neutral, detailing a routine stock option grant and correction of a reporting error. It doesn't contain overtly positive or negative information.
Positives
- The granting of stock options to the CEO could align his interests with those of the shareholders.
- The correction of the reporting oversight demonstrates a commitment to transparency.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry, similar to companies like BioNTech or Moderna.
- The vesting schedule of three years is also typical, aligning with industry norms for retaining key personnel.
- The exercise price is relative to the stock price at the time of the grant, which is a common practice.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CEO.
- The correction of the reporting error enhances transparency and builds trust with stakeholders.
Key Dates
| Date | Description |
|---|---|
| December 13, 2022 | Date of execution of Power of Attorney. |
| May 24, 2023 | Date of the stock option grant. |
| December 4, 2023 | Date of 1-for-35 reverse stock split. |
| April 25, 2024 | Date of 1-for-10 reverse stock split. |
| May 24, 2024 | First vesting date for the stock options. |
| July 18, 2024 | Date of Form 4 filing. |
| May 24, 2033 | Expiration date of the stock options. |
Keywords
Form 4, Stock Options, ZyVersa Therapeutics, Stephen C. Glover, SEC Filing, Beneficial Ownership, Power of Attorney
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.